CAU
MRVI icon

Caxton Associates (UK)’s Maravai LifeSciences MRVI Stock Holding History

Caxton Associates (UK)’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-150,751
Closed -$490K – 924
2025
Q4 		$490K Buy
+150,751
New +$508K 0.01% 509

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caxton Associates (UK)'s MRVI Position: Q1 2026 in Review

Caxton Associates (UK) sold out of Maravai LifeSciences (MRVI) in Q1 2026, closing a stake of 150,751 shares — an estimated $490K sold.

Caxton Associates (UK) first reported a position in MRVI in Q4 2025 and held it in 1 quarter. The position peaked at $490K in Q4 2025. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Caxton Associates (UK) reported no remaining Maravai LifeSciences position as of Q1 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 150,751 Maravai LifeSciences shares in Q1 2026, an estimated $490K.
  • Caxton Associates (UK) first reported a position in Maravai LifeSciences in Q4 2025 and held it in 1 quarter.
  • Caxton Associates (UK)'s Maravai LifeSciences position peaked at $490K in Q4 2025.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.